Sonnet Biotherapeutics Holdings Inc (SONN) — Cash Flow-to-Debt Ratio
Sonnet Biotherapeutics Holdings Inc (SONN) has a Cash Flow-to-Debt Ratio of -0.34x as of June 2025, meaning its operating cash flow of $-1.76 Million could theoretically repay 0% of its total liabilities ($5.10 Million) in one year. See SONN FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Sonnet Biotherapeutics Holdings Inc Cash Flow-to-Debt Ratio (2009–2025)
Historical debt coverage capacity for Sonnet Biotherapeutics Holdings Inc across 15 annual periods. For the full cash flow conversion analysis, see Sonnet Biotherapeutics Holdings Inc (SONN) cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Sonnet Biotherapeutics Holdings Inc (2009–2025)
Year-by-year debt coverage analysis for Sonnet Biotherapeutics Holdings Inc. Check earnings quality score of Sonnet Biotherapeutics Holdings Inc to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.13x | $-12.83 Million | $4.10 Million | ▼ -18.5% |
| 2024 | -2.64x | $-8.61 Million | $3.26 Million | ▲ +30.0% |
| 2023 | -3.77x | $-21.34 Million | $5.66 Million | ▼ -14.1% |
| 2022 | -3.31x | $-27.69 Million | $8.37 Million | ▲ +1.2% |
| 2021 | -3.35x | $-22.55 Million | $6.73 Million | ▼ -6.7% |
| 2020 | -3.14x | $-15.61 Million | $4.97 Million | ▼ -306.9% |
| 2019 | -0.77x | $-2.23 Million | $2.89 Million | ▼ -1890.6% |
| 2017 | -0.04x | $-724.43K | $18.69 Million | ▼ -48.6% |
| 2016 | -0.03x | $-509.16K | $19.52 Million | ▲ +90.1% |
| 2015 | -0.26x | $-5.36 Million | $20.45 Million | ▼ -1.8% |
| 2015 | -0.26x | $-5.36 Million | $20.82 Million | ▲ +15.7% |
| 2013 | -0.31x | $-2.70 Million | $8.85 Million | ▼ -13.0% |
| 2012 | -0.27x | $-1.04 Million | $3.86 Million | ▼ -47264.5% |
| 2011 | 0.00x | $-760.31K | $1.33 Billion | ▲ +99.9% |
| 2009 | -0.87x | $-636.48K | $735.65K | — |